-
Sector Analysis
Obesity in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2031
This report covers the 68 geographical markets and provides an Excel-based forecast model for the obesity market through 2031. Across the 68 markets, sales in the obesity market were $12.3 billion in 2021, growing to $206.5 billion in 2031. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 85% and 84% of 68-market sales in 2021 and 2031, respectively.
-
Sector Analysis
Type 1 Diabetes in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
This report covers the 68 geographical markets and provides an Excel-based forecast model for the type 1 diabetes market from 2023-2033. This publication is an expanded version of the Excel model containing the patient-based forecast (PBF) sales for type 1 diabetes, covered in GlobalData’s report “Type 1 Diabetes: Seven-Market Drug Forecast and Market Analysis”, published in January 2025. In addition to PBF sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report...
-
Sector Analysis
Hyperlipidemia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Hyperlipidemia therapeutics. GlobalData epidemiologists estimate 128,720,003 total prevalent cases of high low-density lipoprotein C (LDL-C) with high triglycerides (TG) in 2024, which is expected to increase to 133,846,798 total prevalent cases in 2029. Most of the marketed hyperlipidemia assets, including both innovator molecules and generic molecules, are enzyme inhibitors, A total of 207 molecules are in development for hyperlipidemia, including 15 drugs in the pre-registration stage,...
-
Sector Analysis
Type 1 Diabetes in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the type 1 diabetes market through 2033. GlobalData estimates sales of T1D therapeutics to be approximately $2.83 billion across the 7MM in 2023. By 2033, GlobalData expects the T1D market to grow at a strong compound annual growth rate (CAGR) of 13.3%, reaching sales of $9.91 billion by the end of the forecast period. Major drivers of T1D market growth over...
-
Sector Analysis
Type 1 Diabetes Epidemiology Analysis and Forecast to 2033
Type 1 Diabetes Epidemiology Report Overview In the 7MM, there were 3,012,498 diagnosed prevalent cases of Type 1 Diabetes Epidemiology in 2023. The market will register an AGR of less than 1% during 2023-2033. Type 1 diabetes (T1D), formally referred to as insulin-dependent diabetes or juvenile diabetes, is a chronic autoimmune disease that predominantly develops in childhood and young adulthood and accounts for approximately 5–10% of all diabetes cases. It is caused by the body’s immune system destroying pancreatic beta...
-
Product Insights
Diabetic Retinopathy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Diabetic Retinopathy Clinical Trial Report Overview A total of 818 diabetic retinopathy clinical trials were conducted as of October 2024. The diabetic retinopathy clinical trial report offers a comprehensive understanding of disease clinical trials across regions, and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. Furthermore, the report includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · Asia-Pacific · North America · ...
-
Product Insights
Dyslipidemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Dyslipidemia Clinical Trial Report Overview A total of 3318 dyslipidemia clinical trials have been conducted as of July 2024. The dyslipidemia clinical trial report provides a comprehensive understanding of the dyslipidemia clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · North America · Europe · Asia-Pacific...
-
Product Insights
Dyslipidemia - Drugs In Development, 2024
Empower your strategies with our Dyslipidemia – Drugs In Development, 2024 report and make more profitable business decisions. Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, and type 2 diabetes. Common...
-
Product Insights
Diabetic Retinopathy - Drugs In Development, 2024
Empower your strategies with our Diabetic Retinopathy – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings in the vision (floaters), blurred vision, fluctuating vision, vision loss, and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy, and tobacco use. The Diabetic Retinopathy drugs in development market research report provide comprehensive information on...
-
Product Insights
Diabetic Macular Edema - Drugs In Development, 2024
Empower your strategies with our Diabetic Macular Edema – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if left untreated. Risk factors include age and diabetes. The Diabetic Macular Edema drugs in development market...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.